Next Article in Journal
A Review of the Recent Advances Made with SIRT6 and its Implications on Aging Related Processes, Major Human Diseases, and Possible Therapeutic Targets
Next Article in Special Issue
A Novel Class of tRNA-Derived Small Non-Coding RNAs Respond to Myocardial Hypertrophy and Contribute to Intergenerational Inheritance
Previous Article in Journal
Calcium-Binding Proteins with Disordered Structure and Their Role in Secretion, Storage, and Cellular Signaling
Previous Article in Special Issue
Nontraditional Cardiovascular Biomarkers and Risk Factors: Rationale and Future Perspectives
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessArticle
Biomolecules 2018, 8(3), 43; https://doi.org/10.3390/biom8030043

Prognostic Value of Iron-Homeostasis Regulating Peptide Hepcidin in Coronary Heart Disease—Evidence from the Large AtheroGene Study

1
Department of General and Interventional Cardiology, University Heart Center Hamburg, 20246 Hamburg, Germany
2
German Center for Cardiovascular Research (DZHK), Partner Site Hamburg, Lübeck, Kiel, 20246 Hamburg, Germany
3
German Center for Cardiovascular Research (DZHK), Partner Site Rhein-Main, 55131 Mainz, Germany
4
Department of Laboratory Medicine, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 8 June 2018 / Revised: 25 June 2018 / Accepted: 26 June 2018 / Published: 28 June 2018
(This article belongs to the Special Issue Biomolecules for Translational Approaches in Cardiology)
Full-Text   |   PDF [372 KB, uploaded 28 June 2018]   |  

Abstract

Iron is essential in terms of oxygen utilization and mitochondrial function. The liver-derived peptide hepcidin has been recognized as a key regulator of iron homeostasis. Since iron metabolism is crucially linked to cardiovascular health, and low hepcidin was proposed as potential new marker of iron metabolism, we aimed to evaluate the prognostic value of hepcidin in a large cohort of patients with coronary heart disease (CHD). Serum levels of hepcidin were determined at baseline in patients with angiographically documented CHD. The main outcome measure was non-fatal myocardial infarction (MI) or cardiovascular death. During a median follow-up of 4.1 years, 10.3% experienced an endpoint. In Cox regression analyses for hepcidin the hazard ratio for future cardiovascular death or MI was 1.03 (95% confidence interval (CI) 0.91–1.18, p = 0.63) after adjustment for sex and age. This association virtually did not change after additional adjustment for body mass index (BMI), smoking status, hypertension, diabetes, dyslipidemia, and surrogates of cardiac function (NT-proBNP), size of myocardial necrosis (troponin I), and anemia (hemoglobin). In this study, by far the largest evaluating the predictive value of hepcidin, hepcidin levels were not associated with future MI or cardiovascular death. This implicates a limited, if any, role for hepcidin in secondary cardiovascular risk prediction. View Full-Text
Keywords: hepcidin; iron; coronary heart disease; biomarker; prognosis hepcidin; iron; coronary heart disease; biomarker; prognosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Zeller, T.; Altay, A.; Waldeyer, C.; Appelbaum, S.; Ojeda, F.; Ruhe, J.; Schnabel, R.B.; Lackner, K.J.; Blankenberg, S.; Karakas, M. Prognostic Value of Iron-Homeostasis Regulating Peptide Hepcidin in Coronary Heart Disease—Evidence from the Large AtheroGene Study. Biomolecules 2018, 8, 43.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top